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Fine Mapping of the Psoriasis Susceptibility Gene PSORS1: A
Reassessment of Risk Associated with a Putative Risk Haplotype
Lacking HLA-Cw6
Cluster 17 Collaboration1
Human leukocyte antigen (HLA)-Cw6 has long been associated with psoriasis, and PSORS1 (psoriasis susceptibility 1),
a major gene for psoriasis susceptibility, has been mapped to its vicinity. A previous analysis identiﬁed multiple risk
haplotypes carrying HLA-Cw6 and one haplotype (cluster 17, HLA-Cw8-B65) that appeared to carry risk for psoriasis
but did not carry HLA-Cw6. This haplotype was very similar to other risk haplotypes for at least 60 kb telomeric to HLA-
C, suggesting identity by descent with the remaining risk chromosomes. The association, however, between psoriasis
and this haplotype as assessed by the transmission/disequilibrium test (TDT) was of borderline signiﬁcance (p-value
0.048). In order to better assess the risk associated with cluster 17, a multicenter collaboration typed additional
subjects for a single marker (M6S161) for which one allele (249 bp) was found only on cluster 17. The new sample
included 1275 pedigrees as well as 300 cases and 913 controls. Transmission of this allele to affected individuals was
examined using the TDT and the pedigree disequilibrium test (PDT), and case–control samples were analyzed by a
trend test across genotype categories. By all methods, the newly acquired genotypes failed to conﬁrm the
association originally reported, despite adequate power. In contrast, the 248 bp allele, which is found on all HLA-
Cw6-positive risk haplotypes as well as several non-risk haplotypes, shows signiﬁcant excess transmission for all
cohorts. Taken together, these results indicate that cluster 17 does not carry a psoriasis-susceptibility allele, and
expand the PSORS1 risk interval to approximately 300 kb.
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Psoriasis is a complex genetic disease whose etiology likely
involves multiple genetic and environmental factors. The
only putative psoriasis locus that has attained a genome-
wide significant lod score in multiple genome-wide linkage
scans is PSORS1 (psoriasis susceptibility 1), which lies in
the major histocompatibility complex (MHC) on human
chromosome 6p21.3 (Trembath et al, 1997; Jenisch et al,
1998; Veal et al, 2001; Zhang et al, 2002). Association of
psoriasis with several human leukocyte antigens (HLA-C,
-B, -DR, -DQ) has also been demonstrated by many groups
(reviewed in Elder et al, 1994) and confirmed by analysis of
polymorphic markers within the MHC (reviewed in Capon
et al, 2002). PSORS1 has been estimated to account for
approximately 35% of the genetic liability to psoriasis
(Trembath et al, 1997). Thus, identification of the PSORS1
gene (or genes) is currently the highest priority for psoriasis
genetics research.
Previous work by some of us attempted to localize
PSORS1 to a smaller interval within the MHC (Nair et al,
2000). Sixty-two microsatellite markers spanning the entire
4 Mb of the MHC were typed in 339 families, and maximum
likelihood haplotypes were constructed. Family-based
association testing of single markers and short (2–5-marker)
haplotypes narrowed the candidate region to a 1.2 Mb
segment in the central MHC. An additional 139 families
were typed for 34 markers in this 1.2 Mb segment.
Haplotypes comprising 34 markers were then constructed
for the combined set of 478 families and the 2156
haplotypes in founders were clustered by an agglomerative
hierarchical method. Requiring 80% identity of haplotypes,
66 haplotype clusters, each represented in at least five
founders, were identified. These clusters were then used to
classify non-founder haplotypes in the combined pedigree
set, and tested for association with the transmission/
disequilibrium test (TDT). Twenty-six of the haplotype
clusters exhibited at least ten independent transmissions
plus non-transmissions from heterozygous parents to
affected children. Of these 26, six (clusters 17, 19, 21–23,
and 25) appeared to impart an increased risk for psoriasis,
when risk is defined as X60% transmission to affected
children. All six of these putative risk clusters share an 8-
marker, 59.4 kb segment of homology, which was desig-
nated RH1. In addition, all clusters except cluster 17 share a
7-marker 126.6 kb segment of homology that lies just
telomeric of RH1, which was designated RH2 (Fig 1).
Although microsatellite alleles differ among risk haplotypes
in the regions immediately flanking both sides of RH1, later
sequencing work revealed that the risk haplotypes are
nearly identical in the those areas.2 This observation is
compatible with the known higher mutation rate of micro-
satellite alleles (Ellegren, 2000), and redefined the candidate
region to include a 140 kb segment lying between HLA-C
and microsatellite M6S190 in the Class I region of the MHC
(Fig 1), with the evidence for both boundaries deriving from
cluster 17.
The sample size for cluster 17 was limited because of the
relatively low frequency of this chromosome. Thus, despite
a transmitted: non-transmitted ratio of 21:10, the TDT p-
value was marginal (p¼ 0.048 using normal approximation
Figure 1
Delineation of the psoriasis suscept-
ibility 1 (PSORS1) risk interval. In both
panels, the risk interval is depicted as
originally defined (RH1 and RH2), after
initial expansion (140 kb risk interval), and
after incorporating new cluster 17 results
(300 kb risk interval). (A) Spatial map of
risk intervals. Key microsatellites are
shown below the distance axis, and
known genes are shown above. All inter-
vals are extended to the first reliable non-
conserved flanking marker or gene. (B)
Microsatellite alleles within risk intervals.
All 34 markers of the six risk haplotype
clusters of Nair et al (2000) are displayed,
in centromeric to telomeric order from left
to right. Alleles at HLA-B and HLA-C are
indicated in boldface type. Ellipses (. . .)
indicate that no allele occurred in 450%
of the founder haplotypes comprising
the cluster. Italicized and non-italicized
numbers indicate that the allele shown
occurred in 50%–80% and 480%,
respectively, of the founder haplotypes
comprising the cluster. Alleles are shaded
when they differ among risk haplotypes
for a marker but are not indicative of a
significant difference in the underlying
sequence of the region. The conserved
alleles of RH1 and RH2 are depicted by
boxes. The two risk intervals, depicted by
bold lines, show the minimum region of
conserved or shaded marker alleles
shared in common by all risk haplotypes
when including or excluding cluster 17 as
a risk haplotype.
2Nair R, Stuart P, Voorhees J, Weichenthal M, Jenisch S,
Christophers E, Elder JT: Manuscript, in preparation.
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of binomial and p¼ 0.071 using exact two-sided binomial).
Also, all risk clusters except 17 carry the HLA-Cw6 allele,
which many groups have shown to be strongly associated
with psoriasis, whereas cluster 17 carries the uncommon
HLA-Cw8 allele, which no other group has implicated in
psoriasis. Therefore, in order to increase sample size, a
collaboration was initiated involving eight additional Eur-
opean groups to the original Ann Arbor/Kiel group. This
collaboration took advantage of our observation that the
249 bp allele at microsatellite M6S161 was highly specific
for cluster 17 and closely related haplotypes mapping
directly adjacent to cluster 17 in the clustering dendrogram
(Nair et al, 2000). Although this observation is based solely
on the original Ann Arbor/Kiel cohort used to define these
clusters (Nair et al, 2000), that cohort was made up largely
of Caucasian Americans whose ancestors come from many
different European countries, making it highly likely that the
249 bp allele is also specific for cluster 17 in the other
cohorts in this study. The results of this effort indicate that
cluster 17 is unlikely to be a risk haplotype, which expands
the critical interval for PSORS1 from a 140 kb segment
encompassing four known genes to a 300 kb segment
containing eight known genes, including HLA-Cw6 and
CDSN (Fig 1).
Results
Allele frequencies The frequency of the 249 bp allele at
M6S161 varied considerably among family cohorts (Table
Ia, complete allele frequency distributions for all cohorts
and confidence intervals for the allele frequencies deter-
mined for the family cohorts are accessible at URL http://
www.psoriasis.umich.edu/cluster17/.) Even though we have
not randomly sampled the populations of these countries,
the observed lack of association of the 249 bp allele with
psoriasis (see below) indicates that the observed frequen-
cies are probably a reasonable estimate of the actual
frequencies in the general population. It has been shown by
others that the Cw8-B65 haplotype of cluster 17 is found
more frequently along the Mediterranean than other parts of
Europe (Imanishi et al, 1992). This finding is borne out by our
data, where frequencies less than 1.4% are seen in
Sweden, Finland, Iceland, Germany, and England, and
frequencies greater than 2.1% are seen in Italy, France, and
the United States (the Ann Arbor/Kiel sample is largely from
the United States, which is home to many individuals of
Mediterranean origin).
The two case–control samples are summarized in Table I.
Note that the frequency of allele 249 in the Ann Arbor and
Table I. Summary statistics for pedigrees and case–control samples used in collaborative study of risk for psoriasis of cluster 17
haplotype (M6S161 allele 249–HLA-Cw8–HLA-B65)
Cohort Country # pedigrees
# dyad
pedigrees
# triad
pedigrees
# triad
and
dyad
pedigrees
# DSP
pedigreesa
# LD
pedigreesb
# founder
chromo-
somes
Frequency
M6S161
allele 249
(a) Pedigree samples
AA/Kiel
(old)
USA/Germany 509 102 376 478 111 484 2204 0.0209
AA/Kiel
(new)
USA/Germany 190 26 118 144 22 151 692 0.0260
Reykjavik Iceland 296 104 96 200 119 249 1163 0.0138
Gothenburg Sweden 196 31 154 185 0 185 736 0.0109
Stockholm Sweden 63 14 34 48 30 51 222 0.0045
Helsinki Finland 90 3 78 81 0 81 357 0.0057
Leicester United
Kingdom
134 55 56 111 35 118 531 0.0132
Muenster Germany 210 38 164 202 18 204 791 0.0101
Evry France 46 4 41 45 42 45 520 0.0250
Rome Italy 50 0 50 50 0 50 200 0.0250
New pedigrees 1275 275 791 1066 266 1134 5212 0.0150
All pedigrees 1784 377 1167 1544 377 1618 7416 0.0167
Cohort Country # cases # controls # total Frequency M6S161 allele 249
(b) Case–control samples
Ann Arbor USA 104 153 257 0.0214
Reykjavik Iceland 196 760 956 0.0120
Total 300 913 1213 0.0140
aDiscordant sib pair (one affected and one unaffected sibling).
bLinkage disequilibrium (i.e., pedigree has at least one triad, dyad, or DSP).
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Reykjavik case–control samples is very similar to its
frequency among founders in the pedigree samples for
these same two countries (1.2% vs 1.4% for Reykjavik;
2.1% vs 2.1 and 2.6% for Ann Arbor).
Power analysis Power to detect association of cluster 17
and psoriasis depends in part upon the genotype relative
risk (GRR) for developing psoriasis when carrying one or
two copies of the cluster 17 haplotype. If cluster 17 is truly
associated with psoriasis, then recombinant haplotype
analysis of the original Ann Arbor/Kiel cohort (Nair et al,
2000) strongly suggests that the cluster 17 haplotype and all
Cw6 haplotypes carry the same PSORS1 risk allele within a
segment of DNA that is inherited identical by descent from a
common ancestor. Accordingly, an estimate of the GRR of a
putative cluster 17 PSORS1 risk allele can be provided by
estimating the GRR of Cw6 in our sample. We base the GRR
estimate on Cw6 haplotypes only rather than on cluster 17
by itself or in combination with Cw6, because multiple
studies have provided incontrovertible evidence that Cw6
haplotypes carry a PSORS1 risk allele, whereas the
evidence for cluster 17 carrying PSORS1 is limited to one
result of marginal significance.
Estimates of GRR for Cw6 in the original Ann Arbor/Kiel
cohort (Nair et al, 2000) are 10.4 for homozygotes and 5.2
for heterozygotes, indicating that the relationship of
psoriasis and PSORS1 approximately follows an additive
mode of inheritance. These risks, however, are expressed
relative to the risk of non-Cw6 carriers, whereas the power
calculations for cluster 17 assume risk is expressed to non-
cluster 17 carriers, many of which will carry at least one
Cw6 haplotype. Including Cw6 carriers among the ‘‘non-
risk’’ genotype category nearly doubles the penetrance of
‘‘non-risk’’ genotypes and thus halves the expected GRR for
the putative cluster 17 PSORS1 allele. Accordingly, a
reasonable estimate of GRR for cluster 17 as a PSORS1
risk haplotype would be  5 for GRR2 and  3 for GRR1.
These GRR values were used to perform power calcula-
tions as described in Subjects and Methods. The new
cohort has 791 pedigrees with at least one triad, and the
frequency of cluster 17 is assumed to be 0.015, the
observed frequency of M6S161 allele 249 in the new
pedigrees. For an additive model with a GRR2 of 5
(GRR1¼3), which is reflective of the actual data, and a
type I error rate of 0.05, power of the two-sided TDT is
99.8%. Importantly, 80% power is still achieved even if
the relative risk of cluster 17 is much lower than that seen
for Cw6 haplotypes. Thus, 80% power is achieved for
GRR2¼ 3.03 under an additive model (GRR1¼ 2.01). More-
over, the true power of our pedigree disequilibrium test
(PDT) analysis of full pedigrees is no doubt substantially
higher than our estimates, which consider only TDT analysis
of independent triads. Results are broadly similar for
dominant and multiplicative models; however, power is
much lower for recessive models (6% for a type I error rate
of 0.05, GRR2¼ 5, GRR1¼1). Complete power curves are
available at URL http://www.psoriasis.umich.edu/cluster17/.
Our original pedigrees showed marginal evidence for
association (TDT p value=0.089), and our power calcula-
tions predict that we should see stronger evidence for
association (i.e., a smaller p-value) with a probability of
499.9% if allele 249 was associated with psoriasis at a
GRR2 of 5, assuming an additive or dominant mode of gene
action. Under a multiplicative model, this probability is still
495%.
Power was also determined for TDT analysis of the new
and old samples combined. For the pooled pedigree
sample, there are 1167 independent triads, and the
observed frequency of M6S161 allele 249 is 0.0167. Power
of the two-sided TDT to detect association of psoriasis and
cluster 17 for a GRR2 of 5 and type I error rate of 0.05 is
essentially 100% under the additive or dominant models,
99% under a multiplicative model, and 6% under a
recessive model. 80% power is achieved if GRR2¼ 2.52
(GRR1¼ 1.76) under the additive model. As expected, the
power of the pooled sample to detect association is
substantially greater than the new sample alone. Thus,
both the new and combined samples appear adequately
powered, and we would expect to replicate our original
association if M6S161 allele 249 were truly associated with
an increased risk of psoriasis.
Family-based analyses Results of the TDT analysis are
shown in Table II. The original cohort described by Nair et al
(2000) suggests association of psoriasis with allele 249: a
65.7% transmission ratio, and p-values of 0.089 (exact) and
0.063 (asymptotic) (Table IIa). The number of transmission
events is higher here (23:12) than in the original publication
(21:10) because the 249 allele occurs on a few haplotypes
that were directly adjacent to but not actually within clus-
ter 17 in the clustering dendrogram. Inclusion of these
haplotypes is justified because they are completely homo-
logous to the cluster 17 consensus for those markers that lie
within or near the PSORS1 candidate region. The new
pedigrees, however, show no evidence for association of
cluster 17 with psoriasis (T:NT¼21:21, p¼1.0). Combining
the new pedigrees with the original cohort also yields no
significant association (43:32, p¼0.25).
Results of the PDT analysis for allele 249 are given in
Table III. The original cohort shows some evidence for
association of cluster 17 with psoriasis, as expected. When
analysis is restricted to triads and dyads, the asymptotic p-
value gives somewhat stronger evidence for marker-trait
association than was determined by the TDT (0.041 vs
0.063), even though the percent transmission is consider-
ably lower (60.9% vs 65.7%). Analysis of discordant sib
pairs (DSP) in the original cohort also shows evidence for
association (D ¼ 0:247, see Subjects and Methods for
definition of D). When triads, dyads, and DSP are combined,
the original cohort shows considerably more significant
association of cluster 17 and psoriasis by the PDT
(D ¼ 0:219, p¼ 0.027) than by the TDT. PDT analysis of
the new pedigrees, however, shows no evidence for
association of cluster 17 and psoriasis, whether the analysis
uses triads and dyads (D ¼ 0:025, %T¼51.3, p¼0.80),
DSP (D ¼ 0:018 , p¼ 0.98), or both ( D ¼ 0:019, p¼0.69).
The combined cohorts also show no significant association
of psoriasis and allele 249. PDT analysis of triads, dyads,
and DSP, however, yields a result that approaches p¼ 0.05
(D ¼ 0:108, p¼0.083). Although the original cohort com-
prises only 29.9% of the 1618 pedigrees amenable to PDT
analysis, it makes up 42.4% of the 92 pedigrees in the total
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cohort that are actually informative for allele 249 on account
of the higher frequency of the 249 bp allele in the original
cohort versus the new pedigrees (2.1% vs 1.5%).
In contrast to the negative results obtained for allele 249,
TDT analysis of the 248 bp allele at M6S161, a common
allele that is found on all HLA-Cw6-positive risk haplotypes
as well as several non-risk haplotypes, shows an excess
transmission for all cohorts, ranging from 54.4% to 66.7%
(Table IIb). The association is moderately significant for the
original Ann Arbor/Kiel cohort (197:151, p¼0.016) and
highly significant for the new pedigrees combined (431:294,
p¼4.1  107) and for the total sample (630:447,
p¼2.7  108). The association of allele 248 with psoriasis
reflects the fact that this allele is carried on all HLA-Cw6-
positive haplotypes. The association of psoriasis with allele
248 (58.5% transmission, Table IIb) is lower than that seen
for HLA-Cw6-positive haplotypes (73.6% transmission (Nair
et al, 2000)) because allele 248, by far the most frequent
allele of M6S161, is also found on many common non-risk
haplotypes.
Results for PDT analysis of allele 248 are shown in Table
IV. As was observed using the TDT (Table IIb), highly
significant evidence of association of psoriasis and allele
248 is seen for the original, new, and combined cohorts.
PDT analysis of triads and dyads gives more striking
evidence for association than TDT analysis (p¼0.0070 vs
0.014 for the original cohort, 4.5  108 vs 3.6  107 for
the new cohort, and 1.4  109 vs 2.5  108 for the total
cohort), although the percent transmission values are very
similar (57.1% vs 56.6% for original, 59.4% vs 59.5% for
new, and 58.6% vs 58.5% for total cohort). Inclusion of DSP
yields even greater significant evidence for association of
psoriasis and the 248 bp allele. Although the p-values for
DSP analysis of allele 248 are less impressive than for triads
Table II. Results of biallelic TDT test (median of 999 runs)
Cohort T:NT % T
Exact
p-valuea
Asymptotic
p-valueb
(a) M6S161 allele 249 (cluster 17)
AA/Kiel (old) 23:12 65.7 0.089 0.063
AA/Kiel (new) 5:3 62.5 0.73 0.48
Reykjavik 2:2 50.0 — —
Gothenburg 5:2 71.4 — —
Stockholm 0:1 0.0 — —
Helsinki 1:1 50.0 — —
Leicester 1:2 33.3 — —
Muenster 5:3 62.5 — —
Evry 1:1 50.0 — —
Rome 0:5 0.0 — —
New pedigrees 21:21 50.0 1.00 1.00
All pedigrees 43:32 57.3 0.25 0.20
(b) M6S161 allele 248
AA/Kiel (old) 197:151 56.6 0.016 0.014
AA/Kiel (new) 62:52 54.4 0.40 0.35
Reykjavik 56:29 65.9 0.0045 0.0034
Gothenburg 76:51 59.8 0.033 0.027
Stockholm 24:12 66.7 0.065 0.046
Helsinki 45:34 57.0 0.26 0.22
Leicester 34:17 66.7 0.024 0.017
Muenster 85:62 57.8 0.069 0.058
Evry 21:17 55.3 0.63 0.52
Rome 30:21 58.8 0.26 0.21
New pedigrees 431:294 59.5 4.1  107 3.6  107
All pedigrees 630:447 58.5 2.7  108 2.5  108
ap-value is exact two-sided binomial and is computed only when there are at least ten informative pedigrees in the cohort; all p-values are nominal
(uncorrected for multiple testing).
bp-value uses the normal approximation to a binomial distribution and is given here for comparison with the normal approximation p-values of the PDT
analysis of Tables III and IV.
TDT, transmission/disequilibrium test; PDT, pedigree disequilibrium test.
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Table III. Results of PDT analysis for cluster 17 (M6S161 allele 249)
Cohort
Triads and dyads only DSP only Triads, dyads, and DSP
# informative
pedigreesa Db % T p-valuec
# informative
pedigrees D p-value
# informative
pedigrees D p-value
AA/Kiel (old) 39 0.218 60.9 0.041 8 0.247 — 39 0.219 0.027
AA/Kiel (new) 10 0.200 60.0 0.32 3 — — 12 0.200 0.093
Reykjavik 4 0.250 37.5 — 3 0.667 — 5 0.188 —
Gothenburg 7 0.429 71.4 — 0 — — 7 0.429 —
Stockholm 1 0.333 33.3 — 1 0.667 — 1 0.500 —
Helsinki 2 0.000 50.0 — 0 — — 2 0.000 —
Leicester 3 0.000 50.0 — 2 0.500 — 5 0.125 —
Muenster 8 0.250 62.5 — 0 — — 8 0.250 —
Evry 8 0.067 53.4 — 5 0.239 — 8 0.062 —
Rome 5 1.000 0.0 — 0 — — 5 1.000 —
New pedigrees 48 0.025 51.3 0.80 14 0.018 0.98 53 0.019 0.69
All pedigrees 87 0.111 55.5 0.13 22 0.113 0.29 92 0.108 0.083
aNumber of informative pedigrees. A pedigree contains an informative triad if there is at least one affected typed child whose parents are typed and at
least one of these parents is heterozygous for M6S161 allele 249. Pedigrees have an informative dyad if the sole typed parent is heterozygous for the 249
allele and the child has a heterozygous M6S161 genotype different from that of the parent. A pedigree contains an informative DSP if it has a sibship with
at least one affected and one unaffected sibling with different M6S161 genotypes and at least one of these genotypes has one or more 249 alleles (the
parents do not need to be typed). See Martin et al (2000) for more details.
bMean standardized D, a scaled measure of linkage disequilibrium for the allele being tested, averaged over all pedigrees that are informative for the
allele. D has a range of [1,1] and is equal to 0 in the absence of linkage disequilibrium (see Subjects and Methods for details).
cp-value is for the ‘‘PDT-avg’’ test statistic of Martin et al (2001). It is based on the w2 distribution and is computed only when there are at least ten
informative pedigrees in the cohort. All p-values are nominal (uncorrected for multiple testing).
PDT, pedigree disequilibrium test; DSP, discordant sib pair.
Table IV. Results of PDT analysis for M6S161 allele 248
Cohort
Triads and dyads only DSP only Triads, dyads, and DSP
# informative
pedigreesa Db % T p-valuec
# informative
pedigrees D p-value
# informative
pedigrees D p-value
AA/Kiel (old) 293 0.141 57.1 0.0070 67 0.202 0.016 310 0.132 0.0041
AA/Kiel (new) 91 0.077 53.9 0.35 13 0.083 0.48 98 0.082 0.30
Reykjavik 74 0.340 67.0 0.0024 52 0.307 0.016 109 0.284 0.0016
Gothenburg 102 0.216 60.8 0.021 0 — — 102 0.216 0.021
Stockholm 28 0.280 64.0 0.016 16 0.393 0.047 33 0.292 0.0059
Helsinki 54 0.093 54.7 0.16 0 — — 54 0.093 0.16
Leicester 46 0.270 63.5 0.013 24 0.260 0.31 61 0.135 0.017
Muenster 113 0.161 58.1 0.051 8 0.650 — 119 0.188 0.029
Evry 35 0.183 59.2 0.13 34 0.120 0.13 39 0.127 0.28
Rome 39 0.128 56.4 0.21 0 — — 39 0.128 0.21
New pedrigrees 582 0.187 59.4 4.5  108 147 0.133 0.0011 654 0.173 1.0  108
All pedrigrees 875 0.172 58.6 1.4  109 214 0.158 4.8  105 964 0.159 1.9  1010
aNumber of informative pedigrees. As in Table III, except calculations refer to allele 248 instead of allele 249.
bMean standardized D. See Table III and Subjects and Methods for details.
cp-Value is for the ‘‘PDT-avg’’ test statistic. See Table III for details. All p-values are nominal (uncorrected for multiple testing).
PDT, pedigree disequilibrium test; DSP, discordant sib pair.
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and dyads because of the smaller numbers of informative
pedigrees, the levels of disequilibrium for triads and dyads
versus DSP are comparable (D ¼ 0:202 vs 0.141 for the
original cohort, 0.133 vs 0.187 for the new cohort, and 0.158
vs 0.172 for the total cohort). Hence, concerns that PDT
analysis of DSP would be adversely affected by the
relatively low penetrance of PSORS1 (i.e., that unaffected
siblings of psoriatics may often be carriers for PSORS1
haplotypes) are apparently unwarranted.
Case–control analysis Table Va gives results for the case–
control analysis of allele 249 (cluster 17). Applying the trend
test to the three genotype categories found no significant
evidence for association of disease and allele 249 within
the Ann Arbor cohort (odds ratio (OR)¼0.31, p¼ 0.12) or
the Reykjavik cohort (OR¼ 1.38, p¼0.45). For these data,
the ‘‘allele’’ and ‘‘serological’’ tests (Sasieni, 1997) would
have given exactly the same p-values as the ‘‘genotype’’
test because there are no homozygotes for the 249 allele.
Although the OR differ for the two cohorts, there is no
significant evidence for heterogeneity in the association
of genotype and disease across cohorts (p¼ 0.093). The
Mantel extension of the linear trend test found no significant
association of allele 249 and psoriasis across both cohorts
(p¼ 0.64). Thus the case–control analysis confirms the
results of the family-based tests.
Table Vb lists results for case–control analysis of
allele 248, which is found on all Cw6-positive haplotypes
as well as many common non-risk haplotypes. The Ann
Arbor cohort shows significant evidence for association of
allele 248 with psoriasis (p¼0.015), whereas the Reykjavik
cohort fails to reach the threshold for significance
(p¼0.090). Linear association appears to be homogeneous
across cohorts (p¼0.31), so it is appropriate to test for
conditional independence. As expected, the Mantel exten-
sion of the trend test across both cohorts provides more
power than the individual cohort tests, finding strong
evidence for association of allele 248 genotype and
psoriasis (p¼ 0.0053). Thus, once again, analysis of case–
control data confirms the results of the pedigree analysis.
Note that the OR for homozygotes is greater than that for
heterozygotes in both cohorts (2.74 vs 2.05 in Ann Arbor
cohort; 1.93 vs 1.75 in Reykjavik cohort), and that the
difference in risk of carrying two versus one copy of the
248 bp allele most closely resembles an additive model. Simi-
lar results have been reported recently by some of us
(Gudjonsson et al, 2003).
Discussion
A critical task in the identification of the PSORS1 gene is to
identify the shortest genetic interval that contains it. This
task is challenged by the substantial linkage disequilibrium
that characterizes the human MHC (Walsh et al, 2003). This
TableV. Results of case–control analysis
Ann Arbor Reykjavik
Psoriatics Controls Total Psoriatics Controls Total
(a) M6S161 allele 249a
249/249 0 0 0 0 0 0
249/other 2 9 11 6 17 23
Other/other 102 144 246 190 743 933
Total 104 153 257 196 760 956
Odds ratio (249/other) 0.31 1.38
Cochran–Armitage test for linear trend w2¼2.37, p¼0.12 w2¼ 0.45, p¼ 0.50
Ann Arbor Reykjavik
Psoriatics Controls Total Psoriatics Controls Total
(b) M6S161 allele 248b
248/248 53 60 113 102 361 463
248/other 41 62 103 83 324 407
Other/other 10 31 41 11 75 86
Total 104 153 257 196 760 956
Odds ratio (248/248) 2.74 1.93
Odds ratio (248/other) 2.05 1.75
Cochran–Armitage test for linear trend w2¼5.96, p¼0.015 w2¼2.88, p¼0.090
aLikelihood ratio test of homogeneous linear association: G2¼ 2.82 (p¼ 0.093). Mantel linear trend test of conditional independence: w2¼ 0.22
(p¼ 0.64).
bLikelihood ratio test of homogeneous linear association: G2¼ 1.05 (p¼ 0.31). Mantel linear trend test of conditional independence: w2¼ 7.78
(p¼ 0.0053).
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collaboration was undertaken because cluster 17 (HLA-
Cw8-B65) was suggested as associated in a previous study,
albeit with a marginally significant p-value of 0.046 (Nair
et al, 2000). This cluster displayed great similarity to other
risk-associated haplotypes in the proximal MHC Class I
region, yet it lacked HLA-Cw6 (Nair et al, 2000). When
combined with subsequent sequence information (see
Introduction), it became evident that the length of the risk
interval depended critically on a more definitive assessment
of the risk associated with cluster 17. As shown in Fig 1, if
cluster 17 is not a genuine risk haplotype, the candidate
region for PSORS1 expands from a 140 kb region en-
compassing four genes to a 300 kb region encompassing
eight genes.
Comparison of haplotype clusters revealed that the 249
bp allele at M6S161 was specific for cluster 17. Indeed,
marker M6S161 and the flanking genes OTF3, TCF19, HCR,
SPR1, SEEK1, CDSN, and STG reside within one of the
seven strongest regions of linkage disequilibrium in the
MHC (Walsh et al, 2003). This finding greatly facilitated
collaboration, because it was possible for each participating
center to type only a single marker as a surrogate for cluster
17. Although different typing methodologies were used
by different groups, the provision of DNA from a single
reference individual (a 248 bp/249 bp heterozygote at
M6S161) allowed for accurate calibration of allele sizes.
The replication set formed by this collaboration provided
no evidence for association between psoriasis and cluster
17 in the TDT (Table IIa), the PDT (Table III), or in the trend
test for case–control genotypes (Table V). Even when
combined with the original cohort that yielded a marginally
significant result (Nair et al, 2000), the data also fail to
identify a significant association between cluster 17 and
psoriasis by either the TDT or the PDT (Tables IIa). These
data are in accord with (but not fully independent of) a study
of over 1000 Icelandic patients with psoriasis, which failed
to identify an association between psoriasis and HLA-Cw8
(Gudjonsson et al, 2003).
We have given careful consideration to the power of
our sample to detect a significant association if one truly
existed. Our power calculations demonstrate excellent
power to detect association, under all reasonable genetic
models, for realistic values of GRR. Although our data set
lacked power under a recessive model, GRR values derived
from our own data and association studies performed on
over 1000 Icelandic psoriatics (Gudjonsson et al, 2003)
strongly suggest that PSORS1 does not act in a recessive
fashion. Our power calculations are conservative, in that
they include only a subset of the individuals and genetic
relationships actually used by our association tests.
Taken together, the findings presented here demonstrate
that cluster 17 is highly unlikely to encode a PSORS1 risk
allele. Although this result extends the length of the risk
haplotype from 140 to 300 kb (Fig 1), it also provides a
much larger number of candidate genes on that haplotype
(eight) than did the previous interval (four). Of these, HLA-
Cw6, the ‘‘WWCC’’ allele at HCR, and ‘‘allele 5’’ at CDSN
remain particularly plausible, whereas the evidence in favor
of the remaining genes is less robust (Asumalahti et al,
2002; Capon et al, 2002). The paucity of recombination
between these alleles has made it extremely difficult to
identify enough informative recombinant individuals to
distinguish the risk associated with each of them. Although
transracial mapping of a Gujarati Indian population has
suggested a co-equal role for HLA-Cw6 and CDSN, but not
for HCR (Capon et al, 2003), other studies of Japanese,
Thai, Chinese, and Spanish psoriatics have failed to confirm
the importance of CDSN allele 5 independently of HLA-Cw6
(Gonzalez et al, 2000; Hui et al, 2002; Chang et al, 2003;
Romphruk et al, 2003). Two additional studies of HCR have
suggested that the WWCC allele at HCR is unlikely to play a
genetically causal role in psoriasis, even though it is highly
associated with the disease (Chia et al, 2001; O’Brien et al,
2001). HCR, however, was recently functionally assayed in
transgenic mouse models, and the risk allele WWCC was
suggested to induce allele-specific effects on the expres-
sion of some genes relevant for psoriasis, even though the
animals remained healthy (Elomaa et al, 2004). Clearly,
additional very large studies involving multiple ethnic/racial
groups will be required to distinguish between these three
attractive candidate genes. This study demonstrates that
such collaborations are feasible and can be productive. An
ongoing study involving ourselves and others will analyze
thousands of psoriatics, family members, and controls,
making use of the emerging resources of the HapMap
project (2003) in an effort to address this important problem.
The use of markers carrying alleles that are specific for
particular haplotype blocks, or, as in this analysis, for
particular combinations of haplotype blocks, will undoubt-
edly lead to substantial savings of effort, time, and cost.
Subjects and Methods
Subjects In addition to the samples supplied by each group of
European collaborators, the Ann Arbor/Kiel group has continued to
collect clinical material (families, single affected individuals with
parents, and cases and controls) since the time of our original
publication (Nair et al, 2000). As shown in Table Ia, these sources
combined to provide an additional 1275 pedigrees for association
testing. The number of pedigrees is shown for each cohort, along
with the subset of this number that contains at least one triad
(affected child with two typed parents), at least one dyad (affected
child with one typed parent) but no triads, or at least one DSP. By
any measure, the new sample contains more than twice the
number of pedigrees in the original cohort of Nair et al (2000).
Combined, the two samples yield a total of 1544 pedigrees for TDT
analysis and 1618 pedigrees for PDT analysis.
The Ann Arbor and Reykjavik groups were also able to provide
case–control samples (Table Ib). Together, these two samples
provide 300 cases and 913 controls, allowing a second indepen-
dent test for association of cluster 17 and psoriasis.
Enrollment of subjects and genotyping was carried out under
protocols approved by the medical ethical committees of each
participating institution. Written, informed consent was obtained
from all subjects. This study was conducted according to the
Declaration of Helsinki Principles at all participating institutions.
Marker typing All members of the pedigree and case–control
samples were typed for microsatellite marker M6S161, which is
one of the markers used to create the 34-marker haplotypes
described by Nair et al (2000). This marker carries an allele of size
249 bp that is highly specific to the cluster 17 haplotype. All of the
other risk clusters (19, 21–23, 25) carry the 248 bp allele at
M6S161, which is the most common allele at this marker and is
also found on many non-risk haplotypes. The M6S161 amplimer
produces several different one-nucleotide variations in allele size,
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because it includes two different length polymorphisms—a TC
dinucleotide repeat and a 1 bp C/-indel (see foonote 2). Each group
performed its own genotyping, utilizing 32P-labeled or fluorescent
oligonucleotide primers by standard methods (Nair et al, 1995; Veal
et al, 2001). DNA from a reference individual known to be
heterozygous for the M6S161 248 and 249 bp alleles was
genotyped in parallel by all groups, allowing calibration of results
and comparison of allele sizes across centers. Each genotyping
center employed its own established procedures to minimize
genotyping errors. Whenever possible, genotyping accuracy was
further assessed by checking for Mendelian inheritance errors.
Family-based association analysis The pedigrees were ana-
lyzed for M6S161 alleles 248 and 249 by two different family-based
association tests—the TDT (Spielman et al, 1993) and the PDT
(Martin et al, 2000; Martin et al, 2001). We utilized the ‘‘PDT-avg’’
test described by Martin et al (2001), which gives equal weighting
to all families, rather than the ‘‘PDT-sum’’ test, which gives greater
weight to larger pedigrees. Both the TDT and PDT were extended
to include dyads when triads were not available.
The value D is a scaled measure of linkage disequilibrium
between the allele being tested by the PDT and the disease
phenotype. It is an alternative to reporting the percentage of
transmitted alleles in the TDT. D has a range of [1, 1] and is equal
to 0 in the absence of linkage disequilibrium. The original description
of the PDT (Martin et al, 2000) provided no standardized measure
of the level of linkage disequilibrium measured by the PDT statistic.
Martin et al do define a random variable D, where Di summarizes
the amount of linkage disequilibrium for all possible triads and DSP
for the ith pedigree in a sample of N-independent pedigrees. The
range of permissible values of D, however, depends upon the
structure of the pedigree and upon the parental genotypes in the
triads, dyads, and DSP (we have extended the analysis to dyads,
as mentioned above). In order to standardize the Di for each
pedigree, we divided it by the maximum possible D value
(conditional on known parental genotypes) for that pedigree. This
restricts the range of D to the [1,1] interval. Mean standardized D
values were then computed over all analyzed pedigrees.
Many of the pedigrees in the sample are large nuclear families
or extended families that contain more than one triad and/or dyad.
Because the TDT is a valid test of association only when the triads
and dyads analyzed are genetically independent, analysis was
restricted to a single triad or dyad randomly selected from each
pedigree. Since results vary depending upon the particular random
selection, the analysis was repeated 999 times with different
random number seeds, and the median result reported. To avoid
bias, we restricted the analysis of dyads to instances where the
parent has a heterozygous genotype different from that of the
affected child (Curtis and Sham, 1995). Although TDT and PDT
were both run as biallelic tests, determination of alleles transmitted
and non-transmitted from heterozygous parents was based on the
full allele diversity of the marker. This permits use of at least some
of the dyads, which would never qualify for unbiased analysis if the
marker alleles were first downcoded to a biallelic system (Curtis
and Sham, 1995).
The biallelic PDT-avg test statistic is asymptotically distributed
as a w2 with one degree of freedom. Unlike the biallelic TDT test
statistic, it is not possible to compute an exact binomial p-value for
the PDT. Hence, for comparison purposes, asymptotic p-values
will be used whenever TDT and PDT results are compared.
Cohorts were analyzed individually and in combination (original
cohort, new cohorts combined, and all cohorts combined). We
considered it permissible to directly analyze the combined data
with family-based tests, because the validity of such tests is not
affected by population stratification or admixture for the locus
being tested (Spielman et al, 1993; Martin et al, 2000).
Case–control association analysis As recommended by Sasieni
(1997), we have analyzed our case–control data as genotypes, in
conjunction with the Cochran–Armitage test for linear trend. The
assumptions of the linear trend test fit the data most optimally under
a multiplicative model, but the trend test is appropriate as long as
the risk for individuals with two copies of the disease-associated
allele is not intermediate between those who carry one or zero
copies. This is certainly the case for PSORS1, which seems to follow
an additive model (see below). Unlike family-based association tests
such as the TDT and PDT, case–control methods are sensitive to
population stratification, so we did not directly combine data for the
Ann Arbor and Reykjavik cohorts. Mantel’s extension of the Mantel–
Haenszel test to allow for ordinal variables (Mantel, 1963) was used
to test for the conditional independence of psoriasis and M6S161
genotype while controlling for cohort. Genotype categories were
assigned scores for the number of test alleles (0, 1, 2), which is
the implicit scoring system of the Cochran–Armitage trend test. The
Mantel test works best when linear association is similar across
strata (cohorts); for this reason, a likelihood ratio test for homo-
geneous linear association was constructed by comparing the
logistic regression models that include and exclude an interaction
term between genotype and cohort.
Power analysis Our sample consists of a variety of family
structures, for which analytical power calculations are unavailable.
To simplify the power analysis, we determined the power of the
TDT to detect association when considering only genetically
independent triads of the new and pooled cohorts, using the first
approximation method of Knapp (1999). This provides a con-
servative estimate of the actual power of our pedigree sample,
since it discards all dyads (used by the TDT and PDT), additional
triads in the family (used by the PDT), and DSP (used by the PDT).
This method also allowed us to compute power for a reasonable
range of alternative hypotheses, basing the alternatives on what
we know about the likely GRR of PSORS1, the observed frequencies
of the 249 bp allele in our cohorts, and reasonable genetic models
(i.e., recessive, dominant, multiplicative, and additive).
We estimated the penetrance, or the probability of disease for
carriers of a particular genotype, using estimates of genotype
frequencies from our previous study of PSOR1 (Nair et al, 2000),
and from 189 US organ transplant donor candidates and 124
German blood donors (Jenisch et al, 1998), each weighted by the
relative contribution of each country to our cohort. We assumed a
population prevalence of 2% for psoriasis. We then used these
penetrance estimates to define GRR, the penetrance of a
designated risk genotype divided by the penetrance for a genotype
that carries zero copies of the allele of interest, which is the key
parameter for the formulas of Knapp (1999).
Note added in proof: While this manuscript was under review, a study of
Sardinian psoriasis by Orru et al (Am J Hum Genet 76:164–171) also
found no evidence for association between psoriasis and Cluster 17
(designated haplotype H in their study).
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